New direction for Alzheimer's research?

Pharmawire examines the likely impact that the failure of the late-stage trial for Flurizan will have on R&D projects in the Alzheimer's arena. Experts say that the research could now head in a new direction. Article

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.